Amneal Pharmaceuticals (AMRX) is back in focus after regulators in Europe issued a positive opinion on Hopledo, a modified release levodopa/carbidopa therapy for Parkinson’s disease, spotlighting the company’s growing central nervous system franchise.

The recent CHMP opinion and Amneal Pharmaceuticals’ addition to multiple Russell 2000 defensive indexes come after a period of strong momentum, with a 30 day share price return of 35.57% and a 1 year total shareholder return of 103.68%.

If this kind of move in Amneal Pharmaceuticals has caught your attention, it could be a good moment to see what else is setting up in the healthcare AI space through our 40 healthcare AI stocks

With Amneal Pharmaceuticals now trading near its US$17.25 analyst price target and carrying a low value score of 2 despite an indicated 67.86% intrinsic discount, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 60% Undervalued

On the most followed narrative, Amneal Pharmaceuticals screens as materially undervalued, with a fair value of $17.25 against a last close of $17.15, built on detailed cash flow and earnings assumptions.

The recent debt refinancing, substantial reduction in annual interest expense, and anticipated tax benefits (from immediate R&D expensing) give Amneal greater financial flexibility to reinvest in high growth areas and pursue vertical integration of biosimilars, which could further enhance future earnings and free cash flow.

Want to see why this narrative still points to a sizable gap between price and intrinsic value? The crux sits in how revenue, margins and future valuation multiples are expected to interact over the next few years, and how those moving parts feed into a single discounted cash flow line.

Result: Fair Value of $17.25 (UNDERVALUED)

However, the Amneal Pharmaceuticals narrative still hinges on easing U.S. generics pricing pressure and successful biosimilar execution, as setbacks could quickly challenge today’s valuation comfort.

Another View on Amneal Pharmaceuticals: Earnings Multiple Check

The SWS DCF model paints Amneal Pharmaceuticals as deeply undervalued, yet the earnings multiple tells a different story. At a P/E of 44.8x versus a fair ratio of 36.8x, the stock screens as expensive compared with both the US Pharmaceuticals industry at 15x and peers at 21.4x. Is the market already paying upfront for much of the expected earnings growth?

Next Steps

If the mixed signals around Amneal Pharmaceuticals leave you unsure, take a closer look at the underlying data and weigh both sides of the story, then review the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Amneal Pharmaceuticals?

Consider looking beyond Amneal Pharmaceuticals when there are other potential opportunities on the radar. Casting a wider net can give you more options to compare.

Use the Simply Wall St Screener to explore ideas that fit your style before others move on them.

• Hunt for mispriced opportunities that combine quality and value by scanning our 43 high quality undervalued stocks.
• Strengthen your watchlist with companies prioritising balance sheet resilience using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot underfollowed prospects with strong fundamentals before they become crowded trades by reviewing the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.